The use ofwalk tests as objective measures to provide a means of monitoring response to treatment is appealing. These tests can be conducted outside the laboratory setting and are typically more feasible to administer than traditional laboratory ergometry. The paper by Eaton and colleagues1 entitled 'The endurance shuttle walking test: a responsive measure in pulmonary rehabilitation for chronic obstructive pulmonary disease (COPD) patients' recently published in Chronic Respiratory Disease Jounzal compared the responsiveness of the endurance shuttle walk test (ESWT) to the six-minute walk test in individuals with COPD undergoing pulmonary rehabilitation. In 17 patients with moderate or severe COPD, a comprehensive multidisciplinary outpatient programme for eight weeks, twice weekly resulted in a large improvement (92%) in ESWT performance [mean (CI) = 302 (104-501) m] with a standardized mean change of 0.54. In contrast, there was only a 17% improvement in distance walked in six minutes [mean (CI) = 47 (3-90) m] with a standardized mean change of 0.32. Eaton and colleagues concluded that the ESWT is a highly responsive measure in individuals with COPD undergoing pulmonary rehabilitation, possibly more so than the six-minute walk test and as such, warrants further evaluation as a measure of treatment effectiveness in this population.1
How do the six-minute walk test and ESWT differ and are they indeed measuring the same thing?
The six-minute walk test measures functional capacity defined as the ability to undertake physically demanding activities of daily living.2'3 This test is ideally administered in an indoor, quiet corridor (20-30 m in length) and subjects are required to walk from end to end covering as much ground as they can in six minutes. Instructions and encouragement should be standardized as variation has been shown to effect performance.3 Subjects are able to rest if they become too short of breath or tired and continue when they are able. The administration of two practice walks is recommended to minimize the learning effect.3 '4 The ESTW is based on the incremental shuttle walk test (ISWT), a measure of maximal exercise capacity. The ISWT requires subjects to walk back and forth along a 10-m path, between two pylons, keeping pace with an audio signal. Speed of walking is increased every minute to a total of 12 levels or speeds, with the number of shuttles increasing at each level. The test is terminated when the subject becomes too breathless to maintain the required speed or if the subject fails to complete a shuttle in the time allowed. Like the ISWT, the ESWT utilizes a 10-m path and audio signal; however, while the ISWT is an incremental test that measures maximal capacity, the ESWT is a constant workload test that evaluates the ability to use that capacity. During the ESWT, speed of walking is equivalent to 85% of each subject's maximal performance assessed by the ISWT. Both the ISWT and ESWT have each been shown to be reliable after one practice trial.5'6
The study by Eaton and colleagues' clearly demonstrated that pulmonary rehabilitation resulted in impressive changes in ESWT performance and less dramatic changes in six-minute walk test distance. Given the careful selection and control of the pace during the ESWT, this constant workload walk test may in fact better assess endurance in patients with COPD. The six-minute walk test is a self-paced measure of functional capacity and exercise endurance is likely only one of the determinants of performance.
Should clinicians and researchers in the field of COPD replace the six-minute walk test with the ESWT in practice and research?
We suggest not yet, and concur with Eaton and colleagues that additional evidence is needed before this test be advocated. Although the ESWT does appear to better reflect endurance capacity, there is no data on how it correlates to traditional laboratory measures of endurance whereas studies have shown that changes in distance walked correlate with changes in Vo2max in patients with COPD.3'7 Additionally, there is no information on interpretability of ESWT scores, either at a given point in time or change scores.
In addition to the evidence supporting each measure, consideration must be given to feasibility, ease of administration and patient tolerance. As acknowledged by Eaton and colleagues, the need for one practice ISWT, one trial ISWT for the calculation of the appropriate speed for the ESWT, one practice ESWT and then one trial of ESWT may be too fatiguing for patients and time consuming for clinicians. The ceiling effect ofESWT also warrants caution in that the clinical utility of the test among individuals with COPD who are high functioning may be compromised. In the study by Eaton and colleagues,1 six of 22 patients (two at admission and four after rehabilitation) achieved maximum performance on the ESWT leaving no room to detect further improvement.
Part of the difficulty inherent in choosing an appropriate measure is the ambiguity and confusion in the concept a researcher or clinician is trying to quantify. The terms functional status, functional capacity, functional tolerance, exercise capacity and exercise tolerance have all been used interchangeably in the literature yet can be argued to encompass different concepts.3 Clinicians and researchers must be clear at the outset as to what their outcome of interest isfunction, endurance, or bothand then select the measure that quantifies that outcome best. These considerations are essential before the ESWT be supported as the walk test of choice for individuals with COPD.
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